FIVE-FOR-CO.,-LTD.
6.3.2019 06:00:18 CET | Business Wire | Press release
Five for Co., Ltd. (Location: Chiyoda-ku Ward, Tokyo, Representative Director: Takayoshi Tanigawa) will open a VR experience entertainment facility, “VR NINJA DOJO” which provides Ninja experience for foreigners visiting Japan on Monday, March 18th, 2019 in Uchikanda, Chiyoda-ku, Tokyo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190305006076/en/
VR NINJA DOJO is an entertainment facility that provides “Ninja Experience” fusing the real and virtual world for foreigners visiting Japan. One of Japanese cultures, “Ninja”, is also literally popular as “Ninja” overseas. The facility is designed with the stylistic beauty inherent in Japan and is a space where you can feel the unique perspective of the Japan world. Also, this facility is designed with our own technology so that the third parties who do not wear a head-mount display can enjoy the virtual world as well. So, you can unite and enjoy the experience even when your group consists of two or more people. Furthermore, since we explain the operation completely in English, foreigners visiting Japan comfortably use the facility. Visitors will take the full proficiency examination to be a Ninja master through the VR experience after they had realistic discipline and training by doing physical activities.
Recently, the number of foreign visitors has been on the rise in Japan. According to Japan National Tourism Organization (JNTO), the total number of foreign visitors to Japan in 2018 exceeded 30,010,000, which is the first time ever recorded over 30 million people and is an increase of 8.7% from the previous year. It is expected that the number of foreign visitors to Japan will further increase by 2020, but there is some change in their consumption behavior. In the past, "entity-oriented consumption" such as purchasing large quantities of home appliances and cosmetics etc. was mainstream. But, as the EC industry has expanded, there is less value in traveling some places in order to purchase goods there. Instead, "situation-oriented consumption" such as taking experience type services including hot spring tours and kimono experiences is on the increase. The new facility in anticipation of the growing inbound demand provides a new entertainment that will definitely become popular among foreign visitors to Japan.
VR NINJA DOJO provides a Ninja experience, which is only available here, with the concept of “The Hospitality of Japanese Culture in both the 'real' and the 'virtual' world."
|
[Contents of the Experience] |
| The required time for a Ninja Experience is from 75 minutes to 90 minutes, and up to 10 persons in one group can participate. |
| Ninja cosplay experience |
| - Ninja discipline and training in the real and the virtual world |
| - Full proficiency examination (VR experience) |
| - VR ceremonial photograph |
| - Presentation of handscroll type certificate |
|
[Details of the Facility] |
||
|
The Name of the Facility: |
VR NINJA DOJO |
|
|
Opening Date: |
March 18th, 2019 |
|
|
Location of the Facility: |
Takebashi Bldg. 1F, 2-15-15 Uchikanda, Chiyoda-ku, |
|
| Tokyo 101-0047 | ||
|
Eligible Person for the Experience: Foreign residents and tourists in Japan |
||
|
- One accompanying Japanese person per a foreigner is free of charge. |
||
| (Ninja costume and the handscroll type certificate are not included.) | ||
|
- There is a special plan available catering to Japanese only. |
||
|
Official Site: |
||
|
[Company Profile] |
||
|
Company Name: |
Five for Co., Ltd. |
|
|
Date of Establishment: |
March 14th, 2017 |
|
|
Representative Director: |
Takayoshi Tanigawa |
|
|
Location: |
Uchikanda Chuo Bldg. 7F, 1-18-13 Uchikanda, |
|
| Chiyoda-ku, Tokyo 101-0047 | ||
|
Business Description: |
VR Entertainment Content Produce & Development |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305006076/en/
Contact:
VR NINJA DOJO PR SBY Co., Ltd. Inada / Arai (Antil Co., Ltd. Akazaki Ichika / Sato Katsuhiko / Yoshida Yusei) TEL: (+81) 3-5572-6061 FAX: (+81) 3-6685-5267 E-mail: vr_ninjadojo@vectorinc.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
